Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Claire N Harrison, Professor, Aaron T. Gerds, MD MS, Jean-Jacques Kiladjian, MD PhD, Konstanze Döhner, Sarah A Buckley, MD, Jennifer A. Smith, PhD, Adam R Craig, MD PhD, John Mascarenhas, MD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4175.

https://doi.org/10.1182/blood-2019-129245

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1323.

https://doi.org/10.1182/blood-2019-123605

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Duplex Sequencing Accurately Detects Variants below 1/100,000 in Genes Recurrently Mutated in Acute Myeloid Leukemia

Jacob E. Higgins, PhD, Lindsey N. Williams, PhD, Sarah A Buckley, MD, Christopher S. Hourigan, DPhil FACP FRCP, Jerald P. Radich, MD, Jesse J. Salk, MD PhD

Blood (2018) 132 (Supplement 1): 2769.

https://doi.org/10.1182/blood-2018-99-115071

Published: 2018

Journal Articles

Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms

Sarah A Buckley, MD, Diana Jimenez-Sahagun, BS, Megan Othus, PhD, Roland B. Walter, MD PhD MS, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 4822.

https://doi.org/10.1182/blood-2018-99-110410

Published: 2018

Journal Articles

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Anna B Halpern, MD, Emily M Huebner, Megan Othus, PhD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Kelda M Gardner, PA-C, Sarah A Buckley, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2017) 130 (Supplement 1): 149.

https://doi.org/10.1182/blood.V130.Suppl_1.149.149

Published: 2017

Journal Articles

A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study

Sarah A. Buckley, MD, Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Anna B. Halpern, MD, Emily M Huebner, Carole Shaw, Paul C. Hendrie, MD PhD, Mazyar Shadman, MD MPH, Pamela S. Becker, MD PhD, Roland B. Walter, MD PhD, Elihu H. Estey, MD

Blood (2016) 128 (22): 2787.

https://doi.org/10.1182/blood.V128.22.2787.2787

Published: 2016

Journal Articles

The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis

Sarah A. Buckley, MD, Brent L. Wood, MD PhD, Megan Othus, PhD, Christopher S. Hourigan, MD PhD, Celalettin Ustun, MD, Michael A. Linden, MD PhD, Todd E. DeFor, MS, Michele Malagola, MD PhD, Christopher G. Kanakry, MD, Bernd Gruhn, MD, Beth Devine, PhD PharmD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 2842.

https://doi.org/10.1182/blood.V128.22.2842.2842

Published: 2016

Journal Articles

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Anna B. Halpern, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L. Scott, MD, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Andrea M. Perdue, PA-C, Tara L. Chen, PharmD, BCOP, Sarah A. Buckley, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 1068.

https://doi.org/10.1182/blood.V128.22.1068.1068

Published: 2016

Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

Anna B. Halpern, MD, Sarah A. Buckley, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L Scott, MD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Stephanie Cassone, MSN, FNP-BC, Tara L. Chen, PharmD, BCOP, Derek L. Stirewalt, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 1064.

https://doi.org/10.1182/blood.V128.22.1064.1064

Published: 2016

Journal Articles

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Asma Anwar, MD, Anna B. Halpern, MD, Megan Othus, PhD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Tara L. Chen, PharmD, Sarah A. Buckley, MD, Kaysey F. Orlowski, Morgan A. Powell, BS, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 1339.

https://doi.org/10.1182/blood.V126.23.1339.1339

Published: 2015

Journal Articles

Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study

Sarah A. Buckley, MD, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 5635.

https://doi.org/10.1182/blood.V126.23.5635.5635

Published: 2015

Journal Articles

The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Sarah A. Buckley, MD, Megan Othus, PhD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2014) 124 (21): 2276.

https://doi.org/10.1182/blood.V124.21.2276.2276

Published: 2014

Journal Articles

Adverse Events During Intensive Induction Chemotherapy For Acute Myeloid Leukemia (AML) Or High-Grade Myelodysplastic Syndromes (MDS)

Sarah A. Buckley, MD, Megan Othus, PhD, Vladimir Vainstein, MD MSc, Janis L. Abkowitz, MD, Elihu H. Estey, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 3899.

https://doi.org/10.1182/blood.V122.21.3899.3899

Published: 2013

Journal Articles

Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Roland B. Walter, MD, PhD, Boglarka Gyurkocza, MD, Barry E. Storer, PhD, John M. Pagel, MD, PhD, Sarah A. Buckley, MD, Mohamed L. Sorror, MD, MSc, Colleen Delaney, MD, MSc, Brent L. Wood, MD, PhD, H. Joachim Deeg, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Brenda M. Sandmaier, MD

Blood (2013) 122 (21): 1317.

https://doi.org/10.1182/blood.V122.21.1317.1317

Published: 2013

Journal Articles

Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia

Vladimir Vainstein, MD MSc, Sarah A. Buckley, MD, Shukron Ofir, MSc, Elihu H. Estey, MD, Janis L Abkowitz, MD, Brent L. Wood, MD, PhD, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 3551.

https://doi.org/10.1182/blood.V120.21.3551.3551

Published: 2012

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults: A Case Series of 30 Patients At a U.S. Tertiary Care Center

Sarah A. Buckley, MD, Daniel Egan, MD, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 4681.

https://doi.org/10.1182/blood.V120.21.4681.4681

Published: 2012

NARROW

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Duplex Sequencing Accurately Detects Variants below 1/100,000 in Genes Recurrently Mutated in Acute Myeloid Leukemia

Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study

The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study

The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Adverse Events During Intensive Induction Chemotherapy For Acute Myeloid Leukemia (AML) Or High-Grade Myelodysplastic Syndromes (MDS)

Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Rapid Rate of Peripheral Blood Blast Clearance Accurately Predicts Complete Remission in Acute Myeloid Leukemia

Hemophagocytic Lymphohistiocytosis in Adults: A Case Series of 30 Patients At a U.S. Tertiary Care Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only